Pharma R&D returns hit six-year low

14 December 2016

Projected returns on investment in research and development (R&D) for the top 12 pharma companies have fallen to their lowest level in six years, reveals a new report from Deloitte’s Centre for Health Solutions.

The projections, which take into account the next 21 years, are down to just 3.7% this year, from a high of 10.1% in 2010, according to the researcher’s annual study, highlighting the increased risk involved in bringing a successful treatment to market.

"Our analysis shows that the current model is not sustainable"

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical